These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8417816)

  • 1. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
    Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E
    Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
    Parker RJ; Eastman A; Bostick-Bruton F; Reed E
    J Clin Invest; 1991 Mar; 87(3):772-7. PubMed ID: 1999494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Han I; Ling YH; al-Baker S; Khokhar AR; Perez-Soler R
    Cancer Res; 1993 Oct; 53(20):4913-9. PubMed ID: 8402681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
    Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF
    Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
    Henkels KM; Turchi JJ
    Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA; Hosking LK; Hill BT
    Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.
    Johnson SW; Swiggard PA; Handel LM; Brennan JM; Godwin AK; Ozols RF; Hamilton TC
    Cancer Res; 1994 Nov; 54(22):5911-6. PubMed ID: 7954422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
    Masuda H; Tanaka T; Matsuda H; Kusaba I
    Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y; Wang J; Xiang D; Wang D; Xin X
    Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.